ixabepilone (BMS 247550)

10/01/2010 - "Ixabepilone, a new treatment option for metastatic breast cancer."
07/01/2015 - "In this review, we summarized data on pharmacodynamics, pharmacokinetics, preclinical and clinical studies of ixabepilone in breast cancer. "
05/01/2014 - "In phase II and III trials, ixabepilone showed efficacy in several patient subgroups and in various stages of breast cancer. "
11/01/2013 - "Phase II randomized trial of weekly and every-3-week ixabepilone in metastatic breast cancer patients."
01/01/2013 - "Ixabepilone administered weekly or every three weeks in HER2-negative metastatic breast cancer patients; a randomized non-comparative phase II trial."

03/01/2008 - "Ixabepilone represents a new treatment option for MBC patients with cancers resistant to available chemotherapeutic agents."
09/01/2008 - "Phase 1, Phase 2, and Phase 3 clinical trials examining the safety and efficacy of ixabepilone and its place in cancer treatment were reviewed. "
03/15/2015 - "Subsequent clinical trials established the clinical efficacy of ixabepilone, leading to its regulatory approval for the treatment of drug-resistant metastatic or locally advanced breast cancers."
05/01/2014 - "The aim of this study was to establish the maximum tolerated dose (MTD), dose-limiting toxicities (DLTs), safety, and pharmacokinetics (PK) of a novel oral formulation of ixabepilone in patients with advanced solid tumors. "
05/01/2014 - "A phase I study of oral ixabepilone in patients with advanced solid tumors."

06/01/2010 - "Efficacy of ixabepilone in ER/PR/HER2-negative (triple-negative) breast cancer."
01/01/2021 - "Recent analyses of subpopulations within large pooled datasets have characterized the clinical benefit for progression-free survival and overall survival for ixabepilone in special populations, such as patients with triple-negative breast cancer or those who relapsed within 12 months of prior treatment. "
08/01/2017 - "Since these resistance mechanisms are common in triple-negative breast cancer (TNBC), ixabepilone may have particular advantages in this patient population. "
06/01/2010 - "Ixabepilone shows notable antitumor activity in patients with triple-negative breast cancer when used in a variety of settings. "
12/01/2018 - "The purpose of this study was to evaluate the safety and efficacy of ixabepilone plus capecitabine in patients with metastatic or locally advanced triple-negative breast cancer (TNBC). "

06/01/2012 - "Phase II trial of weekly ixabepilone in men with metastatic castrate-resistant prostate cancer (E3803): a trial of the Eastern Cooperative Oncology Group."
10/01/2003 - "We conducted a dose-escalation study to determine a safe dose of BMS-247550 to combine with EMP in patients with metastatic prostate cancer. "
06/01/2012 - "Here we report the activity and toxicity of ixabepilone, administered by using a weekly schedule, in men with metastatic castrate-resistant prostate cancer (CRPC). "
06/01/2012 - "Here we evaluate the activity of a weekly ixabepilone in men with metastatic castrate-resistant prostate cancer to minimize hematologic toxicity. "
10/01/2003 - "Chemotherapy-naive patients with castrate-metastatic prostate cancer were treated with intravenous BMS-247550 and oral EMP (280 mg three times daily for 5 days) every 3 weeks. "

01/01/2016 - "Preclinical and clinical studies of ixabepilone in endometrial cancer were analyzed and discussed. "
07/01/2009 - "Phase II trial of ixabepilone as second-line treatment in advanced endometrial cancer: gynecologic oncology group trial 129-P."
01/01/2016 - "Ixabepilone for the treatment of endometrial cancer."
07/01/2009 - "CONCLUSION In a cohort of women with advanced or recurrent endometrial cancer who were previously treated with paclitaxel, ixabepilone showed modest activity of limited duration as a second-line agent."
07/01/2015 - "Phase III randomized trial of second-line ixabepilone versus paclitaxel or doxorubicin in women with advanced endometrial cancer."